DMTK Stock Overview
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
DermTech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.57 |
| 52 Week High | US$16.33 |
| 52 Week Low | US$1.55 |
| Beta | 1.76 |
| 1 Month Change | 161.50% |
| 3 Month Change | 201.08% |
| 1 Year Change | -56.14% |
| 3 Year Change | -59.43% |
| 5 Year Change | n/a |
| Change since IPO | 1.74% |
Recent News & Updates
Recent updates
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16
Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics
Sep 15We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth
Sep 03DermTech: Transforming The Melanoma Diagnosis Landscape
Aug 31DermTech: Becoming More Appealing, Despite Nosebleed Valuation
Aug 09DermTech appoints former Myriad Genetics executive as new chief medical officer
Jun 16We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 05DermTech initiated buy at BTIG on the potential of PLA test
May 03DermTech rises 18% on report Cigna covering early melanoma detection test
Apr 27Did DermTech, Inc. (NASDAQ:DMTK) Insiders Buy Up More Shares?
Feb 11DermTech's melanoma testing patch included in NCCN Guidelines
Jan 13DermTech proposes public offering; shares -5.7%
Jan 06DermTech receives positive medical coverage by Geisinger
Dec 30DermTech: Stickers To Diagnose Cancer
Dec 22DermTech inks agreement with Illinois-based Blue Cross Blue Shield
Nov 20Shareholder Returns
| DMTK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.2% | -0.8% | 1.7% |
| 1Y | -56.1% | 4.4% | -9.6% |
Return vs Industry: DMTK underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: DMTK underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| DMTK volatility | |
|---|---|
| DMTK Average Weekly Movement | 23.9% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DMTK is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 24% a week.
Volatility Over Time: DMTK's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 257 | John Dobak | https://www.dermtech.com |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways.
DermTech, Inc. Fundamentals Summary
| DMTK fundamental statistics | |
|---|---|
| Market Cap | US$168.30m |
| Earnings (TTM) | -US$114.51m |
| Revenue (TTM) | US$14.69m |
11.5x
P/S Ratio-1.5x
P/E RatioIs DMTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMTK income statement (TTM) | |
|---|---|
| Revenue | US$14.69m |
| Cost of Revenue | US$13.56m |
| Gross Profit | US$1.13m |
| Other Expenses | US$115.64m |
| Earnings | -US$114.51m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.79 |
| Gross Margin | 7.68% |
| Net Profit Margin | -779.58% |
| Debt/Equity Ratio | 0% |
How did DMTK perform over the long term?
See historical performance and comparison